Orthopedic regenerative surgical products market seen reaching $7.39 billion by 2030

The Business Research Company says the orthopedic regenerative surgical products market was worth $4.88 billion in 2025 and is projected to hit $7.39 billion by 2030. North America led the market in 2025, while Asia-Pacific is expected to grow fastest as demand rises for non-surgical orthopedic treatments and regenerative therapies.

Why it matters: - The orthopedic regenerative surgical products market is tied to treatment for musculoskeletal conditions that affect mobility, recovery and quality of life. - Rising demand for joint preservation, non-surgical options and regenerative therapies is expanding the addressable market for biologic orthopedic products.

What happened: - The Business Research Company published an orthopedic regenerative surgical products market report covering market size, trends and a global forecast from 2026 to 2035. - The market was valued at $4.88 billion in 2025 and is forecast to reach $5.32 billion in 2026. - The report projects the market will reach $7.39 billion by 2030. - The report identifies North America as the largest regional market in 2025. - The report identifies Asia-Pacific as the fastest-growing region over the forecast period. - The report covers Asia-Pacific, South East Asia, Western and Eastern Europe, North America, South America, the Middle East and Africa. - A free sample is available through the company’s sample page. - The full report is available at the company’s report page.

The details: - Growth in 2025 and 2026 was linked to rising musculoskeletal disorders, growing demand for joint preservation treatments, sports injury management, wider acceptance of regenerative therapies and advances in biologic processing methods. - The forecast through 2030 is supported by adoption of stem cell-based therapies, greater interest in non-surgical orthopedic solutions, expansion of regenerative medicine clinics, more investment in biologics research and higher demand for personalized orthopedic treatments. - The report flags platelet-rich plasma therapies, cell-based regenerative treatments, synthetic bone grafts, minimally invasive regenerative techniques and improved tissue repair outcomes as major trends. - Orthopedic regenerative surgical products are used for joint pain, gout, articular cartilage defects, fibromyalgia, osteoarthritis, trauma and joint replacement issues. - Platelet-rich plasma treatments are described as a preferred nonsurgical option for healing musculoskeletal injuries involving joints, tendons, ligaments and muscles. - The report says orthopedic regenerative surgical products can also address other orthopedic injuries. - The market’s growth is also linked to the increasing prevalence of orthopedic disorders worldwide. - A June 2024 Australian Bureau of Statistics report found musculoskeletal conditions accounted for 12.8% of total disease burden, 23.1% of non-fatal burden and 0.8% of fatal burden in Australia in 2023.

Between the lines: - The forecast points to a market shifting toward less invasive treatment approaches and biologic-based repair methods. - Demand appears to be broadening beyond surgery itself, with clinics and personalized therapies becoming more central to orthopedic care. - The regional split suggests established demand in North America and a faster expansion opportunity in Asia-Pacific.

What’s next: - The report expects continued growth as regenerative medicine clinics expand and biologics research investment increases. - Market momentum may accelerate as minimally invasive regenerative techniques and cell-based treatments gain wider use. - The report also includes new 2026 additions such as market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspots infographics and updated graphics and tables.

The bottom line: - Orthopedic regenerative surgical products are moving from a niche biologics segment toward a larger global market built on non-surgical care, tissue repair and musculoskeletal recovery.